Trimel Pharmaceuticals - A closer look at Tefina Phase II FOD results
28 Luglio 2014 - 4:12PM
InvestorsHub NewsWire
While Trimel (TSX:TRL)
continues to work on securing a commercial licensing transaction
for its recently approved Natesto testosterone nasal gel, the firm
recently provided further encouraging data on its 253-patient Phase
II study for Tefina in female orgasmic disorder (FOD). Trimel
continues to analyse the data and plans to meet with the FDA in
H214, ahead of the next clinical study.
Trimel is a Canadian specialty pharmaceutical company. Its lead
products, Natesto and Tefina, deliver testosterone through a
bio-adhesive nasal gel drug delivery technology platform, for male
hypogonadism and female orgasmic disorder (FOD), respectively.
To view the full research report, click here: http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals4
Click here to view all of Edison's
recently published research.
Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Trilogy International Partners Inc (Borsa di Toronto (TSX)): 0 articoli recenti
Più Trimel Pharmaceuticals Corp Articoli Notizie